A rare case of disseminated amebiasis in a patient on biologic therapy for chronic rhinosinusitis.

Key points: Dupilumab targets Th2‐associated inflammatory mediators to reduce disease burden in CRSwNP.While rare, potential sequelae include viral, helminth, and potentially amebic infections. [ABSTRACT FROM AUTHOR]